Granules

Granules

Vertically integrated API and dosage manufacturer

Overview

Granules India makes APIs, PFIs, and finished dosages, using large-scale, vertically integrated plants that control production from base chemicals to final medicines. Its products include common off-patent APIs like Paracetamol, Ibuprofen, Metformin, and Guaifenesin, and it is expanding into more complex areas such as MUPS, oncology, and peptide therapies with US FDA approvals. The company differentiates itself through full vertical integration, large scale, and a global manufacturing footprint that supports both contract manufacturing and its own branded products, offering supply security and cost competitiveness. Its goal is to deliver reliable, affordable medicines to customers worldwide while growing capabilities in complex therapies and pursuing sustainable practices like green chemistry.

About Granules

Simplify's Rating
Why Granules is rated
C+
Rated B on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Industrial & Manufacturing

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

2014

Get referred to Granules

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q3 FY26 revenue rose 22% to INR 1,388 crores, led by North America and Europe.
  • July 2026 inspections at Genome Valley and Chantilly improved regulatory optionality and capacity.
  • Europe grew 151% year-on-year in FY26, while peptide CDMO opened a new revenue vertical.

What critics are saying

  • FDA warning letter dated February 26, 2025 threatens Gagillapur product approvals until remediation closes.
  • Reuters on April 9, 2026 reported record-keeping and contamination concerns still burden management.
  • Any second FDA action at Gagillapur can shut U.S. launches and damage Granules' generics franchise.

What makes Granules unique

  • Granules integrates APIs, PFIs, and dosages, preserving cost control across the value chain.
  • February 2025 Senn Chemicals acquisition adds peptide CDMO capabilities and European regulated-market access.
  • Granules shipped in 80 countries and won 94 approvals by August 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Recently Posted Jobs

Sign up to get curated job recommendations

Granules is Hiring for 30 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →